Anti-c-Met [12.1]
Invented by Dr Julin Wong at University of Dundee
| Catalogue Number | 152671 |
| Applications | FACS IF IP WB |
| Antigen/Gene or Protein Targets | c-Met, cMet |
| Reactivity | Human |
| Relevance | c-Met is a tyrosine receptor kinase which is activated by its ligand, the hepatocyte growth factor. Activation of c-Met leads to a wide spectrum of biological activities such as motility, angiogenesis, morphogenesis, cell survival and cell regeneration. c-Met is abnormally activated in many tumour types. Aberrant c-Met activation was found to induce tumour development, tumour cell migration and invasion, and the worst and final step in cancer progression, metastasis. |
| Host | Mouse |
| Immunogen | Bacterially expressed human c-Met alpha chain |
| Positive Control | SNU-5, U-87MG and MKN45 cells (negative control: T47D cells) |
| Subclass | IgG1 |
| Myeloma Used | Sp2/0-Ag14 |
| Notes | Epitope: KETKDGFMFL |
| Research Area | Cancer, Cell Signaling & Signal Transduction, Epigenetics & Nuclear Signalling |
Wong et al. 2013. Oncotarget. 4(7):1019-36. PMID: 23859937.
Anti-c-Met antibodies recognising a temperature sensitive epitope, inhibit cell growth.
Europe PMC ID: 23859937
Wong et al. 2013. Oncotarget. 4(7):1019-36. PMID: 23859937.
Anti-c-Met antibodies recognising a temperature sensitive epitope, inhibit cell growth.